We report updated progression-free survival ( PFS ) and overall survival ( OS ) data from a trial that compared capecitabine plus oxaliplatin ( CapeOX ) versus S-1 plus oxaliplatin ( SOX ) for the first-line treatment of metastatic colorectal cancer .